| RESEARCH PAPER
|Year : 1982 | Volume
| Issue : 4 | Page : 309-312
Metoclopramide in tardive dyskinesia
TJ Hemnani, PG Dashputra, RN Sarda
The effect of single intravenous doses of metoclopramide ( 10 mg, 20 mg and 40 mg) have been compared with placebo (saline) in a double blind randomised study in 10 patients with tardive dyskinesia, following long term neurokptic therapy. Tardive dyskinesia rating scores were decreased significantly 6 h after administration of meloclopramide (20 mg and 40 mg), when compared with placebo. Reduction of tardive dyskinasia by metoclopramide. ,aD2 receptor- blocking agent, suggest that D2 receptors may be involved in the mediation of this syndrome.
T J Hemnani
Source of Support: None, Conflict of Interest: None